Best Peptides for Muscle Growth

1. Tesamorelin

Tesamorelin is a stabilized growth hormone releasing hormone analog and one of the few peptides in this space with FDA approval (for HIV-associated lipodystrophy). It is notable for its strong effect on visceral adipose tissue, making it a target-of-choice for stubborn abdominal fat, and has shown cognitive benefits in older adults. Like other GHRH analogs it raises IGF-1, so monitoring is advised. It is more potent on visceral fat than CJC-1295 and is sometimes used as a standalone or stacked with Ipamorelin.

• Body Composition (grade S) — 1 cited study through 2007
• Muscle Growth (grade C) — secondary analyses (Stanley 2014, JAMA) show increased muscle area alongside fat loss

Strongest study: Falutz HIV lipodystrophy, NEJM (2007) — -15% visceral fat @ 26wk · N=412

Full Tesamorelin reference

2. CJC-1295 (DAC)

CJC-1295 (DAC) is the Drug Affinity Complex version of the GHRH analog. The DAC binds albumin and stretches the half-life to roughly a week, giving a sustained elevation of GH and IGF-1 rather than a sharp pulse — convenient for less frequent dosing but a more continuous, less physiological release than the no-DAC form. Almost always run with a GH secretagogue like Ipamorelin. Monitor IGF-1 on cycle.

• Body Composition (grade D) — no human outcome trial; extrapolated from GH/IGF-1 PK data
• Muscle Growth (grade D) — no human outcome trial; extrapolated from GH/IGF-1 PK data
• Sleep Quality (grade D) — no human outcome trial; extrapolated from GH/IGF-1 PK data
• Joint & Tendon Health (grade F) — no human outcome trial; extrapolated from GH/IGF-1 PK data

Strongest study: Teichman Phase I dose-escalation, JCEM (2006) — GH 2-10x and IGF-1 1.5-3x for 6-8 days after one dose · N=66

Full CJC-1295 (DAC) reference

3. Ipamorelin

Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin to trigger a clean pulse of growth hormone from the pituitary, without the cortisol, prolactin, or hunger spikes seen with older secretagogues like GHRP-6. Its selectivity makes it one of the most popular and well-tolerated GH peptides. It is typically paired with a GHRH like CJC-1295 to produce a larger, more physiological GH release. Common goals are recovery, sleep quality, and gradual improvements in body composition. Track IGF-1 to confirm response.

• Body Composition (grade D) — flagship citation is animal pharmacology (Raun 1998); human data is PK-only
• Muscle Growth (grade D) — no direct human muscle-outcome trial; extrapolated from GH/IGF-1 response
• Sleep Quality (grade D) — 2 cited studies through 2003

Strongest study: ghrelin agonist meta, JCEM (2015) — consistent IGF-1 + body comp · review

Full Ipamorelin reference

4. MK-677

MK-677 (Ibutamoren) is a non-peptide, orally bioavailable growth hormone secretagogue that activates the ghrelin receptor (GHSR-1a), the same receptor targeted by injectable GHRPs like Ipamorelin and GHRP-6. Unlike those short-acting peptides, MK-677 has a long plasma half-life of roughly 24 hours, producing sustained, round-the-clock elevations in growth hormone and IGF-1 from a single daily oral dose — no reconstitution or injections required. It was originally developed for GH deficiency, age-related muscle loss (sarcopenia), and cachexia. Commonly cited goals are lean mass, sleep quality, and recovery, with cost/appetite-stimulation and mild fluid retention as the main tradeoffs versus injectable secretagogues. Track IGF-1 and fasting glucose to monitor response.

Full MK-677 reference

5. Follistatin-344

Follistatin-344 is a peptide that binds and neutralizes myostatin, the protein that acts as the body's natural brake on muscle growth — blocking myostatin is the same biological logic behind naturally myostatin-deficient animals (and rare human cases) developing dramatically increased muscle mass. The biology is real, but the human evidence gap is unusually wide: the only human data supporting follistatin's muscle effects comes from a one-time gene-therapy trial in Becker muscular dystrophy patients — a virus delivering the follistatin gene directly into muscle — which is a completely different intervention from the injectable peptide sold by research vendors. That injectable product has no published human studies of its own at any dose.

• Muscle Growth (grade F) — Mendell 2015 (Mol Ther, n=6): gene therapy (viral follistatin gene delivery) improved a 6-min walk test in Becker muscular dystrophy — a different intervention entirely from the injectable peptide.

Strongest study: Mendell follistatin gene therapy, Molecular Therapy (2015) — 4 of 6 Becker MD patients walked farther on a 6-min walk test — gene therapy, not the injectable peptide

Full Follistatin-344 reference

6. IGF-1 LR3

IGF-1 LR3 (Long R3 IGF-1) is a modified version of insulin-like growth factor 1 with an extended half-life and reduced binding to IGF binding proteins, so far more of it stays active in circulation. It promotes muscle cell growth and proliferation (hyperplasia), protein synthesis, and recovery, and is one of the more potent anabolic peptides. Because it acts on insulin receptors it can sharply lower blood sugar — hypoglycemia is a real risk — and being broadly growth-promoting it is contraindicated where any malignancy may be present. Evidence in humans is limited; use is largely experimental.

• Muscle Growth (grade F) — 1 cited study through 2004

Strongest study: Renehan IGF-1 cancer meta, Lancet (2004) — elevated IGF-1 tied to higher prostate / breast / colorectal cancer risk · meta-analysis

Full IGF-1 LR3 reference